CD44 and prostate carcinoma: Collins et al. successfully isolated high-purity CD44+/ integrin α2β1 CD133 + cells (cells co-expressing these three molecules) from primary cultured prostate cancer cells, and confirmed that these cells have multi-directional differentiation, clone formation, self-renewal and strong proliferation potential.